Media about Acadia

 

 

Hetan Technologies S.A., an ISP in Satellite Broadband Internet for private Households & SMEs, debuted on the NewConnect market on 15 April 2015. The company's share price increased at the opening on the first day of 41.77%. Acadia was the Authorised Adviser of the company in the Alternative Trading System.

Hetan Technologies S.A. in media:

 

Venture Capital Research (VCR) is an online stock market game, which mission is transfer knowledge about the specifics of equity financing for high-tech projects at an early stage of development and mechanisms of business angels’ and venture capital funds’ investment decisions. The second edition of the game will start in October 2013. Acadia is one of the partners of the game.

VCR in media:

Investment Fund Managers S.A., a specialized, licensed financial institution offering global investment advisory services to private and corporate clients, has successfully completed an offer of new shares on the NewConnect market. The company raised from new investors 4.15 million zł by issuing 5.18 million shares. July 11, 2013 IFM S.A. debuted on the NewConnect market. Acadia was the Authorised Adviser of the company in the Alternative Trading System.

Investment Fund Managers S.A. in media:

Cleveland International Fund starts activities aiming to obtain investors from CEE region. Licensed by USA government in accordance to EB-5 program, fund, starts from Poland. Acadia is an authorized representative of the CIF in CEE region. 

EB-5 program in media:

Mabion SA is a leading Polish biotechnology company which has been established to introduce to the market the latest generation of drugs based on humanized monoclonal antibodies. Cooperation Acadia with the biotech company Mabion SA resulted in a successful debut on the NewConnect market. In the private placement Mabion SA raised from investors 22.8 million zł and it was than the second largest private offering of shares in the history of the NewConnect.

Mabion S.A. in media:

Proteon Pharmaceuticals S.A. is a biotechnology company, based in Lodz, focusing in the field of bacterial infections in animal health, particularly in chicken production and secondarily in fish farming. Depending on a number of considerations, Proteon will consider a public listing on NewConnect. The Authorised Adviser in the process of alternative market entry is Acadia.

Proteon Pharmaceuticals S.A. in media:

The company is registered in the District Court for Warsaw, Economy Department XIII for National Court Register under number KRS: 0000598123. REGON: 141 477 767. NIP 5213508653. Share capital: 50 000 zł.